RecruitingNot ApplicableNCT07220278

Ongoing Dynamic Choice to Address HIV Treatment Interruption in Malawi

Ongoing Dynamic Choice to Address HIV Treatment Interruption in Malawi (CHOICE)


Sponsor

University of California, Los Angeles

Enrollment

800 participants

Start Date

Nov 17, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Repeat and prolonged treatment interruption (TI) is common and the major threat to HIV epidemic control in eastern and southern Africa. The proposed project will test an innovative long-term dynamic choice intervention for ART clients experiencing TI in Malawi. Findings will provide essential information on how to improve sustained retention among TI client, a critical step to curbing the HIV epidemic. TI clients need long-term, responsive interventions. There are no one-size fits all intervention to support long-term care for TI clients because clients experience vastly different and changing barriers to care. While health facilities do have limited capacity for adding new services, existing services can be packaged differently to meet clients' needs. Long-term, dynamic choice of services is one way to provide responsive services and promotes client ownership over care. The investigators propose to give TI clients long-term, dynamic choice of what services they receive and how they receive it (drawing from key building blocks of DSD). Long-term, dynamic choice puts clients in the driver's seat and may be the best practical strategy to provide long-term and responsive TI interventions that are tailored to clients' evolving life circumstances. Dynamic choice is frequently used for HIV prevention and family planning products, whereby clients select the type of health product that works best for them (i.e., condoms, injectables, etc.). Choice of these services is strongly associated with improved outcomes. The goal of this clinical trial is to determine if CHOICE can improve outcomes in TI clients, compared to standard of care (SOC). Participants will be randomly assigned to either the CHOICE or SOC group, and follow them for 12 months. The primary outcome will be viral suppression at 12 months.


Eligibility

Min Age: 15 Years

Plain Language Summary

Simplified for easier understanding

This study, based in Malawi, is testing a flexible care approach to help people living with HIV who have missed or interrupted their HIV medication (antiretroviral therapy, or ART). Missing doses is common and the study aims to find better ways to support people in staying on treatment. **You may be eligible if...** - You are 15 years or older - You are living with HIV - You started HIV treatment more than 3 months ago (not a brand-new patient) - You are not pregnant - You recently missed your ART appointment by more than 28 days **You may NOT be eligible if...** - You are currently pregnant (pregnant women are served through a separate, specialized program that requires additional coordination) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALCHOICE

Routine HIV counselors will provide person-centered counseling and guide clients through a facilitated choice process to select DSDs and other support services routinely available to participating facilities. ART providers will review client preferences alongside client clinical assessments, resulting in a shared decision making of what DSD and support services is clinical safe and preferred for the client. Clients can change their preferred choice at any point throughout study enrollment. Ongoing, dynamic choice of available DSD models is a feasible and likely safe way to optimize the benefits of choice and provide responsive services for TI clients.


Locations(1)

Partners in Hope

Lilongwe, Malawi

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07220278


Related Trials